Primary Objective:
- Evaluate the response of treatment with gemcitabine at a dose of 250 mg/m2SC in 6-hour infusion combined with cisplatin in patients with unresectable malignant mesothelioma.
Secondary Objectives:
- Evaluate the toxicity of the combination of gemcitabine at a dose of 250 mg/m2 infused over 6 hours in with cisplatin patients with unresectable malignant mesothelioma.
- Evaluate the progression free survival (PFS) and overall survival (OS) in patients with unresectable MM treated with this combination.
Eligibility Criteria
- Inclusion Criteria:
-
- Histologic diagnosis of pleural mesothelioma
- Multidisciplinary assessment and considered not a candidate for resection
- Karnofsky > = 70 or ECOG < 2
- Adequate hematologic, renal and hepatic function
- Exclusion Criteria:
-
- Superior vena cava syndrome, severe bone pain or CNS metastasis
- Not candidate for chemotherapy (poor functional status: ECOG >2)
- The patient refuses to participate
